IP Library Granted Patent US 10,905,737
Granted Patent B2
US 10,905,737 · App. 16/751,836 · Granted Feb 2, 2021

Methods of producing anamorelin hydrochloride having controlled chloride content

Inventors: Shin-itsu Kuwabe (Osaka, JP); Takehiko Yanagimachi (Osaka, JP); Hideyuki Yoshiyama (Osaka, JP); Seemon Pines (Newton, PA); Eleanor de Groot (Houston, TX); Silvina Garcia Rubio (Princeton, NJ); Peter Manini (Giubiasco, CH)
Assignees: Helsinn Healthcare SA; Ono Pharmaceutical Co., Ltd.
A61K38/05A61K9/1682A61P3/04C07D401/06C07D401/12C07K5/06034
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,905,737
App. No.
16/751,836
Granted
Feb 2, 2021
Kind
B2
Abstract

The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.

Claims (27)

1. Anamorelin monohydrochloride having a chloride content ranging from 5.8 to 6.2%, a residual organic solvent concentration less than 5000 ppm, and an inter-batch chloride content that varies by no more than 7%.

2. The anamorelin monohydrochloride of claim 1 in an amorphous state.

3. The anamorelin monohydrochloride of claim 1 , in an isolated state.

4. The anamorelin monohydrochloride of claim 1 , comprising less than 0.5% impurities.

5. The anamorelin monohydrochloride of claim 1 , comprising from 1 to 3% water.

6. The anamorelin monohydrochloride of claim 4 , wherein the impurities are selected from by-products, contaminants, and degradation products.

7. The anamorelin monohydrochloride of claim 6 , comprising a residual organic solvent selected from methanol, butyl acetate, propyl acetate, ethyl acetate, isopropyl acetate, isobutyl acetate, methyl acetate, methylethyl ketone, methylisobutyl ketone, 2-methyltetrahydrofuran and combinations thereof in an amount less than 1000 ppm.

8. The anamorelin monohydrochloride of claim 7 , wherein the residual organic solvent is isopropyl acetate.

9. The anamorelin monohydrochloride of claim 1 , having a purity greater than 99%, based on impurities selected from by-products, contaminants other than residual organic solvents and water, and degradation products.

10. A composition comprising anamorelin monohydrochloride and one or more pharmaceutically acceptable excipients, wherein the composition comprises a chloride content ranging from 5.8 to 6.2%, a residual organic solvent concentration less than 5000 ppm, and an inter-batch chloride content that varies by no more than 7%.

11. The composition of claim 10 , in the substantial absence of anamorelin hydrochloride other than anamorelin monohydrochloride.

12. A process for preparing multiple batches of anamorelin monohydrochloride comprising:

a) dissolving anamorelin free base in an organic solvent to form a solution;

b) mixing said solution with water and hydrochloric acid for a time sufficient to:

i) react said anamorelin free base with said hydrochloric acid, and

ii) form an organic phase and an aqueous phase;

c) separating the aqueous phase from the organic phase;

d) isolating said anamorelin monohydrochloride from said aqueous phase; and

e) repeating steps (a)-(d) multiple times to produce multiple batches of anamorelin monohydrochloride having an inter-batch chloride content that varies by no more than 7%.

13. The process of claim 12 , wherein said water and hydrochloric acid in step b) are added sequentially or concurrently to said solution.

14. The process of claim 12 , wherein said organic solvent is selected from butyl acetate, propyl acetate, ethyl acetate, isopropyl acetate, isobutyl acetate, methyl acetate, methylethyl ketone, methylisobutyl ketone and 2-methyltetrahydrofuran.

15. The process of claim 14 , wherein said organic solvent is isopropyl acetate.

16. The process of claim 12 wherein the anamorelin monohydrochloride is isolated from said aqueous phase by spray drying.

17. The process of claim 12 , further comprising processing the anamorelin monohydrochloride into a finished dosage form.

18. The process of claim 12 , wherein said anamorelin monohydrochloride comprises less than 5000 ppm residual organic solvents.

19. The process of claim 12 , wherein said anamorelin monohydrochloride comprises less than 1% impurities selected from contaminants, by-products, and degradation products, other than residual organic solvents and water.

20. The anamorelin monohydrochloride of claim 1 , in an amorphous state, comprising less than 1% impurities selected from by-products, contaminants, and degradation products.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2023
From: HAMILTON SA LLC
To: HELSINN HEALTHCARE SA; HELSINN THERAPEUTICS (U.S.), INC.; HELSINN BIREX PHARMACEUTICALS LIMITED
Reel/Frame 064961/0567 →
SECURITY INTEREST Recorded Dec 30, 2022
From: HELSINN HEALTHCARE SA; HELSINN THERAPEUTICS (U.S.), INC.; HELSINN BIREX PHARMACEUTICALS LIMITED
To: HAMILTON SA LLC
Reel/Frame 062254/0888 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2020
From: KUWABE, SHIN-ITSU; YANAGIMACHI, TAKEHIKO; YOSHIYAMA, HIDEYUKI; PINES, SEEMON; DE GROOT, ELEANOR; GARCIA RUBIO, SILVINA; MANINI, PETER
To: HELSINN HEALTHCARE SA; ONO PHARMACEUTICAL CO., LTD.
Reel/Frame 051648/0755 →
Continuity (7)
Continuation 16383623 · Apr 14, 2019
Continuation 15963284 · Apr 26, 2018
Continuation 15135051 · Apr 21, 2016
Continuation 14539318 · Nov 12, 2014
Division 13865649 · Apr 18, 2013
Provisional Application 61636108 · Apr 20, 2012
Related Publication 20200276259A1 · Sep 3, 2020